pharmaceutical-investing Ascendis Pharma Files Investigational New Drug Application for Phase 2 Trial of TransCon
Ascendis Pharma Announces Orphan Drug Designation Granted for TransCon PTH as Treatment for Hypoparathyroidism
International Tower Hill Mines Announces Pricing and Upsize of US$65 Million Public Offering of Common Shares and US$40 Million Concurrent Private Placement